This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Maintenance therapy in acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation
Journal of Hematology & Oncology Open Access 06 January 2021
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Tsirigotis P, Byrne M, Schmid C, Baron F, Ciceri F, Esteve J, et al. Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. A review from the ALWP of the EBMT. Bone Marrow Transpl. 2016;51:1431–8.
Cruijsen M, Hobo W, van der Velden W, Bremmers M, Woestenenk R, Bar B, et al. Addition of 10-day decitabine to fludarabine/total body irradiation conditioning is feasible and induces tumor-associated antigen-specific T cell responses. Biol Blood Marrow Transpl. 2016;22:1000–8.
Shaw BE, Mufti GJ, Mackinnon S, Cavenagh JD, Pearce RM, Towlson KE, et al. Outcome of second allogeneic transplants using reduced-intensity conditioning following relapse of haematological malignancy after an initial allogeneic transplant. Bone Marrow Transpl. 2008;42:783–9.
Goodyear O, Agathanggelou A, Novitzky-Basso I, Siddique S, McSkeane T, Ryan G, et al. Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia. Blood. 2010;116:1908–18.
Cany J, Roeven M, Hoogstad-van EJ, Hobo W, Maas F, Franco FR, et al. Decitabine enhances targeting of AML cells by CD34(+) progenitor-derived NK cells in NOD/SCID/IL2Rg(null) mice. Blood. 2018;131:202–14.
de Lima M, Giralt S, Thall PF, de Padua SL, Jones RB, Komanduri K, et al. Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study. Cancer. 2010;116:5420–31.
El-Cheikh J, Massoud R, Fares E, Kreidieh N, Mahfouz R, Charafeddine M, et al. Low-dose 5-azacytidine as preventive therapy for relapse of AML and MDS following allogeneic HCT. Bone Marrow Transpl. 2017;52:918–21.
de Lima M, Oran B, Champlin RE, Papadopoulos EB, Giralt SA, Scott BL, et al. CC-486 maintenance after stem cell transplantation in patients with acute myeloid leukemia or myelodysplastic syndromes. Biol Blood Marrow Transpl. 2018;24:2017–24.
Tamura A, Ishida T, Saito A, Yamamoto N, Yokoi T, Uemura S, et al. Low-dose azacitidine maintenance therapy after allogeneic stem cell transplantation for high-risk pediatric acute myeloid leukemia. Pediatr Blood Cancer. 2018;65:e27284.
Pusic I, Choi J, Fiala MA, Gao F, Holt M, Cashen AF, et al. Maintenance therapy with decitabine after allogeneic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndrome. Biol Blood Marrow Transpl. 2015;21:1761–9.
Acknowledgements
We express our gratitude to all the participants for contribution to this study, and we also extend our thanks to all the patients and their family in this study. This study was funded by National Natural Science Foundation of China (81873443, 81400155, and 81500146), Frontier Clinical Technical Project of the Science and Technology Department of Jiangsu Province (BE2017655), Jiangsu Provincial Medical Talent (ZDRCA2016045), Jiangsu Natural Science Foundation of China (BK20150356 and BK20140374), Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD), Major Natural Science Research Projects in institutions of higher education of Jiangsu Province (19KJA210002)Â and Top-notch young health talents (to CQ), 5th Suzhou health professional program.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Ma, Y., Qu, C., Dai, H. et al. Maintenance therapy with decitabine after allogeneic hematopoietic stem cell transplantation to prevent relapse of high-risk acute myeloid leukemia. Bone Marrow Transplant 55, 1206–1208 (2020). https://doi.org/10.1038/s41409-019-0677-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41409-019-0677-z
This article is cited by
-
Post-transplant maintenance therapy in acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation harmonizing multiple therapeutic modalities including targeted therapy, immunotherapy and cellular therapy
International Journal of Hematology (2023)
-
Maintenance therapy in acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation
Journal of Hematology & Oncology (2021)
-
Low-dose decitabine as part of a modified Bu-Cy conditioning regimen improves survival in AML patients with active disease undergoing allogeneic hematopoietic stem cell transplantation
Bone Marrow Transplantation (2021)
-
Decitabine
Reactions Weekly (2020)